Related Articles
Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines
Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells
Co-treatment of wild‑type EGFR head and neck cancer cell lines with afatinib and cisplatin
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells